Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study is a multi-center open-label, dose-escalation, dose-expansion, and a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary efficacy of MT-8421.

Next Previous
Trial Profile

A Phase 1 study is a multi-center open-label, dose-escalation, dose-expansion, and a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary efficacy of MT-8421.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MT-8421 (Primary)
  • Indications Carcinoma; Cervical cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Molecular Templates

Most Recent Events

  • 02 Nov 2023 According to Molecular Templates media release, the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421 for the treatment of advanced solid tumors.
  • 10 Aug 2023 According to Molecular Templates media release, company expect the first patient to be enrolled in this study in 3Q 2023.
  • 09 Mar 2023 According to Molecular Templates media release, the company has received IND clearance by the United States Food and Drug Administration ("FDA") to initiate this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top